Antibe Therapeutics Inc
TSX:ATE

Watchlist Manager
Antibe Therapeutics Inc Logo
Antibe Therapeutics Inc
TSX:ATE
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: 4.7m CAD

Antibe Therapeutics Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Antibe Therapeutics Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Antibe Therapeutics Inc
TSX:ATE
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Non-Reccuring Items
$4m
CAGR 3-Years
-77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Non-Reccuring Items
-CA$20.7m
CAGR 3-Years
78%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Non-Reccuring Items
-CA$18.4m
CAGR 3-Years
44%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Non-Reccuring Items
-$1.6m
CAGR 3-Years
79%
CAGR 5-Years
51%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Antibe Therapeutics Inc
Glance View

Market Cap
4.7m CAD
Industry
Pharmaceuticals

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.

ATE Intrinsic Value
Not Available

See Also

Back to Top